Literature DB >> 19005983

The prevalence of low selenium levels in adult patients undergoing bone marrow transplantation: a brief communication.

Molouk Hadjibabaie1, Masoud Iravani, Ahmad Reza Shamshiri, Zahra Zaker, Asadollah Mousavi, Kamran Alimoghaddam, Babak Bahar, Ebrahim Kalantar, Ardeshir Ghavamzadeh.   

Abstract

Selenium (Se) is an essential trace element, and its deficiency is considered to be important in various types of cancer. There are just a few data regarding this issue among adult patients with hematological malignancy. Serum Se levels were determined in 22 adult patients candidates for bone marrow transplantation (BMT) in Iran. The mean serum Se levels before BMT was 19.91 microg/l (from 12.00 to 62.00 microg/l), and almost all the patients had low Se serum levels (normal serum Se level: 46-143 microg/l). The level of Se 20 days after BMT was 22.53 microg/l, which did not show any significant changes. Most of the patients did not suffer from malnutrition, as they had mostly normal albumin levels. Even though the results of this study showed that Se deficiency is common among our hematological malignant patients, it can not be concluded that these low Se levels are causally related to cancers for which BMT is undertaken. Further studies are needed to evaluate the Se levels at diagnosis before treatment effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005983     DOI: 10.1080/01635580802196107

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  4 in total

1.  Dietary selenium for the mitigation of radiation injury: effects of selenium dose escalation and timing of supplementation.

Authors:  Fritz Sieber; Sarah A Muir; Eric P Cohen; Brian L Fish; Marylou Mäder; Ashley M Schock; Bryan J Althouse; John E Moulder
Journal:  Radiat Res       Date:  2011-07-08       Impact factor: 2.841

Review 2.  Selenium and selenoproteins in prostanoid metabolism and immunity.

Authors:  Fenghua Qian; Sougat Misra; K Sandeep Prabhu
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-01-30       Impact factor: 8.250

3.  Selenium suppresses leukemia through the action of endogenous eicosanoids.

Authors:  Ujjawal H Gandhi; Naveen Kaushal; Shailaja Hegde; Emily R Finch; Avinash K Kudva; Mary J Kennett; Craig T Jordan; Robert F Paulson; K Sandeep Prabhu
Journal:  Cancer Res       Date:  2014-05-28       Impact factor: 12.701

Review 4.  Therapeutic Benefits of Selenium in Hematological Malignancies.

Authors:  Melanie A Ehudin; Upendarrao Golla; Devnah Trivedi; Shobha D Potlakayala; Sairam V Rudrabhatla; Dhimant Desai; Sinisa Dovat; David Claxton; Arati Sharma
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.